FDA’s Approvals in 2025 Favored Follow-Ons Over Breakthroughs
- Eve Lu
- 1 day ago
- 5 min read
A closer look reveals how the new administration is dismantling the traditional biopharma roadmap.
On paper, the FDA’s performance in 2025 suggests a high-functioning agency. With 55 new drugs and vaccines cleared for approval, the volume matches historical averages.
However, a January 2026 Nature report reveals that this productivity masks a fundamental shift toward incrementalism. While the agency maintained output despite leadership turnover and staffing reductions, the majority of "new" approvals were reformulations and follow-ons rather than novel scientific breakthroughs.
This trend reflects a broader industry focus on defensive life-cycle management (LCM) as blockbuster patents approach their expiration dates.
The Scientific Outliers: Validating New Modalities
Despite the prevalence of incremental updates, 2025 produced several landmark approvals that establish new benchmarks for specific therapeutic classes:
Non-Opioid Pain Management: Vertex Pharmaceuticals secured approval for Journavx (suzetrigine), the first in a new class of non-opioid treatments for acute pain. This represents a rare instance of a major scientific "first" addressing a profound public health need.
Ophthalmology Innovation: Alcon’s Tryptyr (acoltremon) introduced a novel mechanism for dry eye disease, utilizing nerve stimulation to increase tear production rather than traditional topical anti-inflammatories.
Oncology Precision: AbbVie’s Emrelis became the first c-Met-directed antibody-drug conjugate (ADC) approved for advanced non-small cell lung cancer. With oncology accounting for nearly 33% of all 2025 approvals, this molecule validates the continued shift toward highly targeted, high-energy delivery systems.
Strategic Data Point: While oncology remains the dominant sector, the success rate for novel mechanisms in 2025 was approximately 20% lower than the five-year average, as capital shifted toward de-risked line extensions.
The LCM Trap: Protecting the Patent Cliff
A significant portion of the "Class of 2025" was dedicated to extending the commercial life of existing blockbusters. These reformulations serve a dual purpose: improving patient delivery and creating new IP moats to delay the entry of biosimilars.
Merck successfully transitioned its top-selling oncology asset, Keytruda, to a subcutaneous formulation. By offering a version that can be administered under the skin rather than through a vein, Merck intends to maintain its $200,000-a-year price point while shifting patients to a delivery method with fresh patent protection.
Similarly, Novo Nordisk secured approval for the first oral version of semaglutide (Wegovy) for weight management. Novo Nordisk plans to price the oral version at $149 per month, an aggressive volume-grab designed to broaden the market ahead of Eli Lilly’s expected oral entry in early 2026. Analysts view this pricing strategy as a defensive maneuver to secure payer preference before generic pressure or direct competitors saturate the metabolic space.
Leadership and the "Great Reset"
The 55 approvals occurred during the most volatile period of institutional transition in the agency’s history. The shift to the new administration has placed the FDA at the center of a very public debate regarding the boundary between scientific rigor and political accountability.
The new leadership, influenced by the administration's "MAHA" (Make America Healthy Again) platform, has initiated a systemic audit of the agency's internal functions. The focus has moved from traditional "consensus-based" review to a model of deregulatory speed.
The Leadership Friction: The resignation of career veterans like CBER Director Peter Marks underscores the tension between the agency’s legacy guardrails and the new mandate for total transparency.
Administrative Squeeze: Staffing cuts and budget realignments are forcing the FDA to do more with less, leading to an increased reliance on manufacturer-provided data and accelerated review timelines that bypass traditional advisory committee scrutiny.
Vaccine Oversight: Transparency vs. Institutional Trust
Nowhere is the politicality of the FDA more evident than in vaccine oversight. The administration’s focus on "data liberation" has forced a radical change in how clinical trial results are presented to the public.
While career scientists maintain that the current oversight is rigorous, the new leadership has prioritized the publication of raw trial data and the reduction of perceived "industry-agency" overlaps. This has created a bifurcated reality:
The Regulatory Shift: 2026 will see the implementation of more stringent post-market surveillance requirements paired with faster "at-speed" approvals.
The Market Risk: For manufacturers, this creates a "validation gap." A drug may reach the market faster, but it faces a higher hurdle in maintaining public trust and long-term insurance coverage in a climate of increased skepticism.
2026 Roadmap: Accelerating Toward Decoupling
As we move into 2026, the FDA is transitioning from a period of "bridge-building" to a period of "active realignment." The upcoming year will be defined by three strategic pillars:
Real-World Evidence (RWE) Dominance: As traditional Phase 3 staffing remains constrained, the FDA will move toward making RWE the primary vehicle for accelerated approvals and line extensions.
The BIOSECURE Act Influence: The agency is increasingly aligning its regulatory priorities with national security goals, specifically the "decoupling" of the biopharma supply chain from high-risk foreign entities.
Consumer Sovereignty: The regulatory focus is shifting toward "nutritional and supplemental" oversight, as the agency seeks to address the root causes of chronic illness through food and lifestyle-based interventions alongside traditional pharmacotherapy.
A Bridge Year for Biopharma
The FDA’s 2025 record is a testament to the industry’s ability to maintain high-volume output through life-cycle management rather than pure discovery. The "Class of 2025" functioned as a bridge, allowing major players to stabilize their revenue bases through oral and subcutaneous pivots while the institutional framework of the FDA stabilized.
For investors and executives, the key takeaway is that volume is no longer a proxy for innovation. In a high-friction regulatory environment, the most successful firms are those that can master the art of the line extension while maintaining a small, high-conviction pipeline of genuine scientific firsts.
Read more about the impact of federal research funding cuts on the future of medicine and learn about the most anticipated drug launches of 2025.
Further Reading:
If you liked this article:
Share this article with your network on LinkedIn with your thoughts or perspectives. Make sure to tag us @HealthcareInsights to join the conversation.
Subscribe to our free newsletter, HealthcareIn Quicktakes. You'll never miss an article, and will get access to exclusive reports.
Check out our library of articles and reports on biotech, healthcare, policy, and business.
Who We Are: At Healthcare Insights, we're covering the transformation of healthcare and bringing our readers the most pertinent takes on key issues in medicine, biotech, healthcare policy, and business. Our Spotlight Series ✦ features thoughts from the most influential figures in healthcare, including Nobel Prize-winning scientists shaping tomorrow's treatments and business leaders bringing new therapies to market. We strive to publish coverage that is authentic, impartial, and independent of any financial or political motive. For more information regarding our editorial standards, read our statement. If you'd like to contact the Editor, use this form to get in touch.
If you'd like to stay in the loop, make sure to subscribe to our free newsletter, HealthcareIn Quicktakes, and follow us @healthcareinsights across our social channels, including LinkedIn.
©️ Copyright 2026 Healthcare Insights
All Rights Reserved
Legal Disclaimer:
The information provided in this article has been collected from various academic publications, industry reports/analyses, regulatory guidelines, media coverage, and legal analyses. The information provided is for general information purposes only and should not be construed for medical, legal, financial, or professional advice. Readers are advised to seek independent professional guidance where relevant. While we strive to ensure the accuracy and timeliness of our coverage, we claim no liability, representations, or warranties of any kind about the completeness, suitability, accuracy, reliability, authorship, or availability of this article and all pertaining data within this article. Neither the author nor the publication will assume liability for any loss or damage arising from the use of the information provided in the article. The information within this article may be outdated or inaccurate over time, and neither the author nor the publication are obligated to update or revise such information. We reserve the right to modify, remove, or substantially edit the article, including the disclaimer, at any time.
